Trump's change of tone prompted by daughter Ivanka?

March 2, 2017

Washington, Mar 2: Behind the scenes at the White House, US President Donald Trump's daughter Ivanka was a key advocate for the more measured, less combative tone he struck in his speech to a joint session of Congress on Tuesday night, officials said.

Ivanka

The biggest speech of Mr Trump's month-old presidency was the product of a 10-day effort with his top aides. While he unveiled no significant changes to policy, the tone of Mr Trump's speech was a far cry from his bleak "American carnage" inaugural address when he took office on January 20.

The Republican president dropped some of the fierce rhetoric that had been a staple of his first weeks in office. He called for national unity and avoided a repeat of his attacks on Democratic opponents and media organisations.

Polls conducted immediately after the speech showed a clear majority of Americans approved of the softer approach and aides described Trump as buoyed by the reception.

A senior White House official said Ivanka Trump made recommendations for the speech during a brainstorming session in the Oval Office on Sunday, helping her father decide on a new approach aimed at easing concerns over whether he had the right temperament to govern effectively.

"He had a lot of voices around him giving him ideas and suggestions that he incorporated, but he really set out to achieve that optimistic tone and that was something she was supportive of. She encouraged him to do that," one official said, speaking on condition of anonymity.

"She had a role," said another. "She helped set the tone."

Ivanka Trump also persuaded her father to speak favourably about affordable child care and paid family leave, policies she has long backed and which could draw support from Democrats in Congress, said another official with some knowledge of how the speech evolved.

"Her fingerprints are visible on the tone, but especially on those parts of it like maternity leave that matter to her," the official said.

'REACHING OUT'

Ivanka Trump, 35, the president's older daughter, has emerged as an influential informal adviser for her father, particularly on issues important to women and minorities.

After his election victory last November, she stepped away from her business interests in New York to move to Washington and is frequently seen at her father's events.

A White House official said Mr Trump was the principal author of the speech but had a lot of help in drafting it, including from his daughter.

Mr Trump made the final changes to his speech during a marathon session on Tuesday, working closely with Vice President Mike Pence, chief strategist Steve Bannon, chief of staff Reince Priebus and chief speechwriter Stephen Miller.

Ivanka Trump's husband, Jared Kushner, is a senior White House adviser with particular interest in trade deals and Middle East diplomacy.

The couple has been among the president's closest confidants since his election campaign, and Mr Kushner also helped in the drafting of the speech to Congress.

Others involved in the last round of deliberations were White House aides Hope Hicks, Kellyanne Conway and Sean Spicer. Ivanka Trump was not in the sessions on Tuesday.

Ivanka Trump accompanied her father to Dover Air Base in Delaware on February 1 to welcome home the remains of US Navy SEAL William "Ryan" Owens, who was killed in a raid on Al Qaeda in Yemen.

At the speech on Tuesday, Owens' widow, Carryn Owens, wept openly when Mr Trump led the crowd in applauding her husband's service. Standing next to her was Ivanka Trump.

Presidential historian Thomas Alan Schwartz of Vanderbilt University said it was hard to find a similar example in recent history of a presidential daughter having a big influence.

"It's a way of reaching out on social issues and social welfare issues or issues that sometimes the Republicans are less identified with," he said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
June 4,2020

Jun 4: A malaria drug President Donald Trump took to try to prevent COVID-19 proved ineffective for that in the first large, high-quality study to test it in people in close contact with someone with the disease.

Results published Wednesday by the New England Journal of Medicine show that hydroxychloroquine was no better than placebo pills at preventing illness from the coronavirus.

The drug did not seem to cause serious harm, though -- about 40% on it had side effects, mostly mild stomach problems.

 “We were disappointed. We would have liked for this to work,” said the study leader, Dr. David Boulware, an infectious disease specialist at the University of Minnesota.

“But our objective was to answer the question and to conduct a high-quality study,” because the evidence on the drug so far has been inconclusive, he said.

Hydroxychloroquine and a similar drug, chloroquine, have been the subject of much debate since Trump started promoting them in March.

Hydroxychloroquine has long been used for malaria, lupus, and rheumatoid arthritis, but no large studies have shown it or chloroquine to be safe or effective for much sicker patients with coronavirus, and some studies have suggested the drugs may do harm.

Trump took a two-week course of hydroxychloroquine, along with zinc and Vitamin D, after two staffers tested positive for COVID-19, and had no ill effects, according to results of his latest physical released by his doctor Wednesday.

Federal regulators have warned against hydroxychloroquine's use except in hospitals and formal studies because of the risk of side effects, especially heart rhythm problems.

Boulware's study involved 821 people in the United States and Canada living with someone diagnosed with COVID-19 or at high risk of getting it because of their job -- doctors, nurses, ambulance workers who had significant exposure to a sick patient while not wearing full protective gear.

They were randomly assigned to get either the nutrient folate as a placebo or hydroxychloroquine for five days, starting within four days of their exposure. Neither they nor others involved in the research knew who was getting which pills.

After 14 days in the study, 12 per cent on the drug developed COVID-19 symptoms versus 14 per cent in the placebo group, but the difference is so small it could have occurred by chance, Boulware said.

“There's basically no effect. It does not prevent infection,” he said of the drug. Even if it were to give some slim advantage, “we'd want a much larger effect” to justify its use and risk of side effects for preventing illness, he said.

Results were no different among a subgroup of participants who were taking zinc or vitamin C, which some people believe might help make hydroxychloroquine more effective or fight the coronavirus.

There are some big caveats: The study enrolled people through the Internet and social media, relying on them to report their own symptoms rather than having them tracked in a formal way by doctors.

Participants were not all tested for the coronavirus but were diagnosed as COVID-19 cases based on symptoms in many cases. And not all took their medicines as directed.

The results “are more provocative than definitive,” and the drug may yet have prevention benefits if tried sooner or in a different way, Dr. Myron Cohen of the University of North Carolina at Chapel Hill wrote in a commentary in the journal.

Others were glad to see a study that had a comparison group and good scientific methods after so many weaker reports on hydroxychloroquine.

“This fits with everything else we've seen so far which suggests that it's not beneficial," said Dr. Peter Bach, director of a health policy center at Memorial Sloan Kettering Cancer Center in New York.

This study was in younger relatively healthy people, but the results “would make me very discouraged about trying to use this in older people” who are most vulnerable to serious illness from the coronavirus, Bach said.

“If it does work, it doesn't work very well.” Dr. Dan Culver, a lung specialist at the Cleveland Clinic, said there's still a chance that giving the drug sooner than four days after someone's exposure to the virus may help prevent illness.

But the study “takes 'home run' off the table” as far as hopes for the drug, he said.

The study was mostly funded by David Baszucki, founder of Roblox, a California-based game software company, and other private donors and the Minnesota university.

Boulware also is leading a study testing hydroxychloroquine for treating COVID-19. The study is finished and results are being analyzed now.

On Tuesday, the journal Lancet posted an “expression of concern” about a study it published earlier this month of nearly 15,000 COVID-19 patients on the malaria drugs that tied their use to a higher risk of dying in the hospital or developing a heartbeat problem.

Scientists have raised serious questions about the database used for that study, and its authors have launched an independent audit.

That work had a big impact: the World Health Organization suspended use of hydroxychloroquine in a study it is leading, and French officials stopped the drug's use in hospitals. On Wednesday, the WHO said experts who reviewed safety information decided that its study could resume.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
April 23,2020

Geneva, Apr 23: The World Health Organisation (WHO) on Wednesday (local time) said that the COVID-19 crisis will not end any time soon, with several countries only in the initial stages of the fight against the virus.

"Make no mistake, we have a long way to go. Coronavirus will be with us for a long time. There is no question that stay at home orders and other physical distancing measures have successfully suppressed transmission in many countries," WHO chief Tedros Adhanom Ghebreyesus said in a press conference.

"Most countries are in the early stages of their epidemics. And some, which were affected early in the pandemic, are now starting to see a resurgence in the number of cases," he added.

COVID-19 has infected more than 2.6 million people around the world and a total of 1,83,027 people have died due to coronavirus, according to data from US-based Johns Hopkins University.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
April 28,2020

Geneva, Apr 28: The global death toll from the novel coronavirus has increased over the past 24 hours by nearly 5,000 to top 198,000, the World Health Organisation (WHO) said.

According to the latest WHO data, 85,530 new cases of infection have been registered globally over the past day, with 4,982 deaths.

The overall number of COVID-19 cases worldwide increased to 2,878,196 and the death count reached 198,668.

There are 1,359,380 confirmed cases and 124,525 deaths in Europe.

The number of cases in the Americas total 1,140,520, with 58,492 deaths.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.